Risen (Suzhou) Pharma Tech Co., Ltd.

Privately held: no public share price · China

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
PI3K-alpha (mutant-selective)Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 2
Amyloid-beta (Aβ)Small molecule
Alzheimer's Disease

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
JS105Phase 1/2Advanced Solid Tumors
Est. primary completion 2027-02-26 · NCT06208410 · CT.gov ↗
What to watch
2029 (2)
May 2029 (2)
RP902Phase 2Mild Cognitive Impairment (MCI)
Est. primary completion 2029-05 · NCT07579884 · CT.gov ↗
What to watch
JS105Phase 3Breast Cancer
Est. primary completion 2029-05-31 · NCT07207070 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.